Sleep Research Peptide

DSIP

Delta Sleep-Inducing Peptide • Nine-Amino-Acid Neuropeptide

DSIP is an experimental nonapeptide studied for possible effects on sleep architecture, stress regulation, pain, withdrawal symptoms, and neuroprotection. Human studies are old, small, and inconsistent, so realistic expectations and careful risk framing are essential.

Sleep Quality Slow-Wave Sleep Neuroprotection Research Variable Response

Protocol Snapshot

DSIP Quick Reference

Verified Vendors

DSIP

Compare Verified Vendors

Current price and availability
Price per mg and vial-size comparison
Testing and fulfillment details

Compare

View Price Index

Community Dose

100–500mcg

Once daily, typically 30–60 minutes before bed.

Cycle Length

4–8 weeks

Then take similar time off, or at least 2–4 weeks.

Routes

SubQ or Intranasal

Route-specific dosing and preparation appear below.

Primary Use

Sleep

Designed for short bedtime trials with response tracking.

Peptide Grade

GradeC

DSIP’s sleep-architecture and stress-signaling rationale is intriguing, and some users report deeper sleep, vivid dreams, or better recovery. However, controlled human evidence remains sparse and inconsistent, its receptor and exact mechanism remain unresolved, and many users report little or no noticeable benefit.

Research Community Safety

Foundation

Research context, mechanisms, and practical use cases

What is DSIP?

DSIP stands for Delta Sleep-Inducing Peptide. It is a naturally occurring nine-amino-acid peptide first described in the 1970s after Swiss researchers isolated DSIP-like material from the cerebral venous blood of rabbits during experimentally induced slow-wave sleep.

Its sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Early research linked the peptide to delta-wave activity, sleep regulation, endocrine signaling, stress responses, and pain modulation. DSIP has also been studied for its ability to cross the blood-brain barrier, although its endogenous biology, receptor, precursor, and exact physiological role remain unresolved.

Unlike conventional sedatives, DSIP is not generally described as a direct “knockout” agent. The theory is that it may influence sleep architecture and help normalize disturbed sleep rather than simply suppress consciousness. That distinction remains provisional because published human findings are mixed.

Evidence Reality Check

Small studies from the 1980s reported improved sleep duration, fewer awakenings, or better daytime function, but later controlled work in chronic insomnia found modest or limited benefit. DSIP should not be presented as a proven treatment for insomnia.

DSIP is rapidly degraded in vitro, with reported half-life estimates around 15 minutes. Carrier binding or other biological factors may extend activity in vivo, but no modern human pharmacokinetic profile has been established.

DSIP is not FDA approved. Its US compounding status has changed over time and remains under active FDA review, so it should not be described as a currently approved compounded therapy.

Potential DSIP Benefits

The evidence base includes small older human studies and more recent animal research. Findings are mixed and do not establish broad clinical efficacy.

Sleep Quality

Some older studies reported longer sleep, fewer awakenings, faster sleep onset, or improved subjective sleep quality. Results in chronic insomnia were inconsistent, and one controlled study concluded that short-term treatment was unlikely to provide major therapeutic benefit.

Sleep Architecture

Early human work suggested DSIP could improve disturbed sleep without clearly suppressing REM sleep. Because the studies were small and methodologically dated, this should not be treated as a settled effect.

Stress Response

Animal studies suggest stress-protective effects under hypoxia and possible modulation of endocrine stress signaling. Human evidence for reliable cortisol reduction is limited.

Pain Relief

A 1984 clinical pilot involving patients with chronic severe pain reported reductions in pain severity and improved mood, with some patients reducing analgesic use. The study was small and exploratory.

Withdrawal Support

An older 107-patient study reported favorable outcomes during opiate and alcohol withdrawal. These findings have not been confirmed in modern randomized trials and should not replace medically supervised detoxification.

Growth Hormone Support

Because growth hormone release is linked to slow-wave sleep, improved sleep could indirectly support normal GH physiology. Direct GH-stimulating effects remain uncertain and are not established in modern human trials.

Neuroprotection

A 2021 rat stroke study found improved motor recovery after intranasal DSIP at 120mcg/kg, despite no significant reduction in infarct size. This remains animal evidence only.

Protocol Planning

Dosing, cycling, and preparation

DSIP Dosing Protocol

The following schedules reflect community and clinic practice, not a modern published dose-finding program. No FDA-approved human dose exists.

Subcutaneous Protocol

Dose

100–500mcg

Conservative Start

100mcg to assess response

Frequency

5 nights on / 2 nights off

Timing

30–60 minutes before bed

Cycle

4–8 weeks, followed by similar time off or at least 2–4 weeks off

Intranasal Protocol

Dose

200–500mcg

Conservative Start

200mcg to assess response

Frequency

5 nights on / 2 nights off

Timing

30–60 minutes before bed

Cycle

4–8 weeks, followed by similar time off or at least 2–4 weeks off

Example Use

One 100mcg spray in each nostril = 200mcg total

Critical

Confirm the bottle’s measured output before calculating mcg per spray

What the Intranasal Research Actually Shows

Intranasal DSIP has been examined in a small human neurophysiology study involving P300 brain-response measurements and in animal research involving stroke recovery. Those studies support the route as biologically plausible, but they do not establish an effective intranasal dose for insomnia or validate current community spray protocols.

Cycling

A common community cycle is 4–8 weeks using a 5-nights-on / 2-nights-off schedule, followed by a break of similar length or at least 2–4 weeks off. Receptor adaptation remains theoretical rather than established, so response should be reassessed before beginning another cycle.

DSIP Reconstitution

10mg Vial

Diluent

2mL bacteriostatic water

Concentration

5mg/mL

500mcg

10 units on a U-100 insulin syringe

200mcg

4 units on a U-100 insulin syringe

Storage

Refrigerate after reconstitution

Reconstitution Calculator

Intranasal Preparation

Diluent

Sterile, preservative-free 0.9% sodium chloride

Final Mixture

10mg brought to 10mL total volume

Device

Metered bottle verified to deliver 0.1mL per spray

Per Spray

100mcg

Storage

Refrigerate and place away from the door as temps fluctuate.

DIY Nasal Prep Essentials

Useful supplies for intranasal DSIP prep

0.9% Sterile Saline AmpoulesPreservative-free single-use saline for nasal-prep workflows. Metered Nasal Spray BottlesUse bottles with known spray output when calculating mcg per spray. 3mL Transfer SyringesUseful for moving measured saline volumes during preparation. 70% Isopropyl AlcoholFor prep-area cleanup and clean handling around materials.

Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Users commonly describe deeper, more continuous sleep with fewer middle-of-the-night awakenings.
Many report feeling calmer and more rested on waking without the heavy grogginess associated with conventional sleep aids.
Vivid dreams, stronger dream recall, and occasional lucid dreaming are frequently reported.

Negative Reports

Some users notice little or no effect despite an adequate trial period.
Higher doses are sometimes reported to disrupt sleep or cause next-day sedation.
Some users report temporary rebound sleep difficulty after prolonged daily use.
Intranasal use can cause temporary nasal dryness or irritation.

Stacking & Synergy

Potential DSIP pairings and tracking context

DSIP Stacking & Synergy

DSIP + Epitalon

The pairing rationale is that Epitalon supports circadian timing through the pineal gland, while DSIP targets sleep quality after sleep begins. Using DSIP against a badly mistimed circadian clock may be one reason some users report little or no effect.

DSIP + Pinealon

Pinealon is used for broader neuroregulatory and circadian support, while DSIP focuses on sleep depth and continuity. This pairing may be most useful when poor sleep is accompanied by cognitive fatigue or disrupted day-night signaling.

DSIP + GH Peptides

Community users sometimes pair DSIP with CJC-1295, ipamorelin, or tesamorelin when nighttime dosing appears to disrupt sleep.

DSIP + Semax or Selank

Some users combine morning Semax or Selank with bedtime DSIP for daytime cognitive support and nighttime sleep optimization. No published interaction data exists.

Use caution with sedatives, benzodiazepines, opioids, antihistamines, alcohol, or other sleep aids because additive sedation is possible even though DSIP’s exact receptor mechanism is unresolved.

Free with login

Track in Journal

Track DSIP with the markers that matter most for this compound.

Dose, route, timing, and cycle day.
Sleep latency, overnight awakenings, and perceived sleep depth.
Next-day alertness, vivid dreams, mood, and adverse effects.

Start Tracking

Safety Notes

Side effects, contraindications, and precautions

DSIP Side Effects

Older clinical studies generally described DSIP as well tolerated over short treatment periods. However, sample sizes were small, study designs were dated, and long-term safety has not been established.

Statements such as “no dependency,” “no respiratory depression,” or “no rebound insomnia” reflect limited short-duration observations, not definitive proof across prolonged or unsupervised use.

Common User Reports

Mild headache.
Temporary grogginess when the dose is too high.
Slight mood fluctuations.
Vivid dreams.

Less Common Reports

Brief anxiety.
Extended sleepiness into the next day at higher doses.
Temporary worsening of sleep after stopping prolonged daily use.

DSIP Contraindications and Precautions

Do Not Use If You Have

Known hypersensitivity to DSIP or any formulation component.
Pregnancy or breastfeeding, because no safety data exists.

Use Caution With

Concurrent sedatives, benzodiazepines, sleep medications, alcohol, or sedating antihistamines.
Concurrent opioid use, because both sedation and opioid-pathway interactions are incompletely understood.
Severe chronic insomnia, where controlled evidence suggests only modest benefit at best.
Kidney or liver impairment, because human clearance data is limited.

Drug Interactions

No well-established interaction profile exists. Sedatives and sleep aids may produce additive effects. Opioid interactions are theoretical and should be treated cautiously.

Regulatory Status

DSIP is not FDA approved in the United States. FDA has previously treated DSIP as a substance of concern in compounding policy, and in 2026 the agency began reconsidering the status of several peptides, including DSIP. It should not be represented as an approved compounded medication.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

We rate DSIP as a useful but highly individual sleep peptide. For those who respond well, it can deliver deeper, more restorative sleep, improved HRV, and better recovery by helping restore normal sleep patterns and taking the edge off the stress axis.

That said, a large portion of people see little to no benefit, likely due to genetic differences in how their bodies process it. Community reports show wide variation in response rates, with many users falling into the non-responder category.

Important context: DSIP will not fix bad sleep hygiene. If you’re drinking caffeine late, scrolling in bed or binging shows into the wee hours of the night, no peptide is going to save you. Sleep hygiene sits upstream of every sleep tool. DSIP is often misused because people treat it like “Ambien in a vial” — expecting to run themselves into the ground all day, administer before bed, and wake up brand new and it just doesn’t work that way.

The best way to know if it’s actually working for you is objective data from a good sleep tracker (Oura, Apple Watch, etc.). Subjective feelings alone are often unreliable.

End of the day, definitely worth testing if sleep optimization is a priority and your fundamentals are already solid. Not a universal fix and works best for those who randomly wake up in the middle of the night or toss and turn a lot.

We like it and use DSIP periodically. We also found that running it 3–5 consecutive days followed by 2–3 days off works best. When or if the results fade, take a break for 1–2 weeks and start again.